The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
Open accessAbstract
OBJECTIVES: VSL#3 is a high-potency probiotic mixture that has been used successfully in the treatment of pouchitis. The primary end point of the study was to assess the effects of supplementation with VSL#3 in patients affected by relapsing ulcerative colitis (UC) who are already under treatment with 5-aminosalicylic acid (ASA) and/or immunosuppressants at stable doses. METHODS: A total of 144 consecutive patients were randomly treated for 8 weeks with VSL#3 at a dose of 3,600 billion CFU/day (71 patients) or with placebo (73 patients). RESULTS: In all, 65 patients in the VSL#3 group and 66 patients in the placebo group completed the study. The decrease in ulcerative colitis disease activity index (UCDAI) scores of 50% or more was higher in the VSL#3 group than in the placebo group (63.1 vs. 40.8; per protocol (PP) P=0.010, confidence interval (CI)₉₅(%) 0.51-0.74; intention to treat (ITT) P=0.031, CI₉₅(%) 0.47-0.69). Significant results with VSL#3 were recorded in an improvement of three points or more in the UCDAI score (60.5% vs. 41.4%; PP P=0.017, CI₉₅(%) 0.51-0.74; ITT P=0.046, CI₉₅(%) 0.47-0.69) and in rectal bleeding (PP P=0.014, CI₉₅(%) 0.46-0.70; ITT P=0.036, CI₉₅(%) 0.41-0.65), whereas stool frequency (PP P=0.202, CI₉₅(%) 0.39-0.63; ITT P=0.229, CI₉₅(%) 0.35-0.57), physician's rate of disease activity (PP P=0.088, CI₉₅(%) 0.34-0.58; ITT P=0.168, CI₉₅(%) 0.31-0.53), and endoscopic scores (PP P=0.086, CI₉₅(%) 0.74-0.92; ITT P=0.366, CI₉₅(%) 0.66-0.86) did not show statistical differences. Remission was higher in the VSL#3 group than in the placebo group (47.7% vs. 32.4%; PP P=0.069, CI₉₅(%) 0.36-0.60; ITT P=0.132, CI₉₅(%) 0.33-0.56). Eight patients on VSL#3 (11.2%) and nine patients on placebo (12.3%) reported mild side effects. CONCLUSIONS: VSL#3 supplementation is safe and able to reduce UCDAI scores in patients affected by relapsing mild-to-moderate UC who are under treatment with 5-ASA and/or immunosuppressants. Moreover, VSL#3 improves rectal bleeding and seems to reinduce remission in relapsing UC patients after 8 weeks of treatment, although these parameters do not reach statistical significance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In IBD, the probiotic mixture VSL#3, which contains bifidobacteria of different species, was able to reduce the UC symptoms in adults (144, 145) as well as the remission of the disease in children (84).”
From Bifidobacteria and Their Health-Promoting Effects (2017) · cites this paper as [145]
In the citing paper
“Both demonstrate that high doses improve disease activity scores”
From The gut microbiota and host health: a new clinical frontier (2016) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The gut microbiota shapes intestinal immune responses during health and disease
Round, J. L., & Mazmanian, S. K. (2009) · Nature Reviews Immunology · doi:10.1038/nri2515 · Cited by 5,029
A microbial symbiosis factor prevents intestinal inflammatory disease
Mazmanian, S. K., Round, J. L., & Kasper, D. L. (2008) · Nature · doi:10.1038/nature07008 · Cited by 2,340
Kornbluth, A. A., & Sachar, D. B. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,032
Gionchetti, P., Rizzello, F., Venturi, A., Brigidi, P., Matteuzzi, D., Bazzocchi, G., Poggioli, G., Miglioli, M., & Campieri, M. (2000) · Gastroenterology · doi:10.1053/gast.2000.9370 · Cited by 1,485
Kruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037747 · Cited by 1,285
Podolsky, D. K. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109263251306 · Cited by 1,226
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial
Gionchetti, P., Rizzello, F., Helwig, U., Venturi, A., Lammers, K. M., Brigidi, P., Vitali, B., Poggioli, G., Miglioli, M., & Campieri, M. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00171-9 · Cited by 1,147
Rembacken, B., Snelling, A. M., Hawkey, P. M., Chalmers, D. M., & Axon, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06343-0 · Cited by 1,100
Probiotic bacteria enhance murine and human intestinal epithelial barrier function
Madsen, K., Cornish, A. S., Soper, P., McKaigney, C. J., Jijon, H. B., Yachimec, C., Doyle, J. S. G., Jewell, L. D., & Simone, C. D. (2001) · Gastroenterology · doi:10.1053/gast.2001.27224 · Cited by 1,096
Kruis, W., SCHÜTZ, E., Fric, P., Fixa, B., Judmaier, G., & Stolte, M. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.00225.x · Cited by 774
Flagged first, then by citations
Cited by
Sorted by citations
The gut microbiota and host health: a new clinical frontier
Marchesi, J. R., Adams, D. H., Fava, F., Hermes, G. D. A., Hirschfield, G. M., Hold, G., Quraishi, M. N., Kinross, J., Smidt, H., Tuohy, K. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309990 · Cited by 2,302
Probiotics and prebiotics in intestinal health and disease: from biology to the clinic
Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R., & Rastall, R. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0173-3 · Cited by 2,059
Large-scale association analyses identify host factors influencing human gut microbiome composition
Kurilshikov, A., Medina-Gomez, C., Bacigalupe, R., Radjabzadeh, D., Wang, J., Demirkan, A., Le Roy, C. I., Raygoza Garay, J. A., Finnicum, C. T., Liu, X., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00763-1 · Cited by 1,786
ACG Clinical Guideline: Ulcerative Colitis in Adults
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000152 · Cited by 1,594
“In 1 clinical trial using VSL#3® as add-on therapy to 5-ASA, endoscopic improvement was not achieved (109).”
MethodDignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Danese, S., & Fiocchi, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1102942 · Cited by 1,153
Self-citationAnti-Inflammatory and Immunomodulatory Effects of Probiotics in Gut Inflammation: A Door to the Body
Cristofori, F., Dargenio, V. N., Dargenio, C., Miniello, V. L., Barone, M., & Francavilla, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.578386 · Cited by 991
“boulardii (143) and VSL#3 (144, 145) are the most studied strains compared to 5-ASA.”
BackgroundThe gut microbiota and inflammatory bowel disease
Matsuoka, K., & Kanai, T. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-014-0454-4 · Cited by 804
“#3 to conventional therapy was more efficacious in remission induction in active UC patients [62, 63].”
Actinobacteria: A relevant minority for the maintenance of gut homeostasis
Binda, C., Lopetuso, L. R., Rizzatti, G., Gibiino, G., Cennamo, V., & Gasbarrini, A. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.02.012 · Cited by 828
Self-citationKhan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T., & Zhang, C. (2019) · Pathogens · doi:10.3390/pathogens8030126 · Cited by 771
ESPEN guideline: Clinical nutrition in inflammatory bowel disease
Forbes, A., Escher, J., Hébuterne, X., Kłęk, S., Krznaric, Z., Schneider, S., Shamir, R., Stardelova, K., Wierdsma, N., Wiskin, A. E., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.12.027 · Cited by 625
“A GRADE analysis indicated that the quality of evidence supporting this outcome was low due to very sparse data (35 events) [287].”
BackgroundRetractedIntestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis
Tojo, R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15163 · Cited by 533
Wang, W., Chen, L., Zhou, R., Wang, X., Song, L., Huang, S., Wang, G., & Xia, B. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01500-13 · Cited by 509
“Several clinical trials have demonstrated the efficacy of VSL#3, a mixture of eight different probiotics, for the treatment of UC patients (5, 6), and single-species probiotic treatment, such as one with Escherichia coli Nissle 1917, Bifidobacterium, or Lactobacillus rhamnosus GG, also displays efficacy in the managem…”
BackgroundAn update on the use and investigation of probiotics in health and disease
Sanders, M. E., Guarner, F., Guerrant, R., Holt, P. R., Quigley, E. M., Sartor, R. B., Sherman, P. M., & Mayer, E. A. (2013) · Gut · doi:10.1136/gutjnl-2012-302504 · Cited by 503
Bifidobacteria and Their Health-Promoting Effects
Hidalgo-Cantabrana, C., Delgado, S., Ruiz, L., Ruas-Madiedo, P., Sánchez, B., & Margolles, A. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0010-2016 · Cited by 490
“In IBD, the probiotic mixture VSL#3, which contains bifidobacteria of different species, was able to reduce the UC symptoms in adults (144, 145) as well as the remission of the disease in children (84).”
BackgroundCui, L., Guan, X., Ding, W., Luo, Y., Wang, W., Bu, W., Song, J., Tan, X., Sun, E., Ning, Q. X., et al. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.10.259 · Cited by 469
Lang, A., Salomon, N., Wu, J. C., Kopylov, U., Lahat, A., Har‐Noy, O., Ching, J. Y. L., Cheong, P. K., Avidan, B., Gamus, D., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.02.019 · Cited by 434
Feuerstein, J. D., Moss, A. C., & Farraye, F. A. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.018 · Cited by 415
Systematic review with meta-analysis: The efficacy of probiotics in inflammatory bowel disease
Derwa, Y., Gracie, D. J., Hamlin, P. J., & Ford, A. C. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14203 · Cited by 393
Sáez‐Lara, M. J., Gómez‐Llorente, C., Plaza‐Díaz, J., & Gil, Á. (2015) · BioMed Research International · doi:10.1155/2015/505878 · Cited by 419
Turner, D., Levine, A., Escher, J., Griffiths, A., Russell, R., Dignass, A., Dias, J., Bronský, J., Braegger, C., Cucchiara, S., et al. (2012) · Journal of Pediatric Gastroenterology and Nutrition - JPGN · doi:10.1097/mpg.0b013e3182662233 · Cited by 402
ESPEN guideline on Clinical Nutrition in inflammatory bowel disease
Bischoff, S. C., Bager, P., Escher, J. C., Forbes, A., Hébuterne, X., Hvas, C. L., Joly, F., Kłęk, S., Krznarić, Ž., Ockenga, J., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2022.12.004 · Cited by 399
“Of these, 12 included patients with mild-moderatelyactive disease [276,278,280, 281,283 e 285,287,289 e 292], and nine included patients in remission [273 e 275,277,279,282,286,288].”
BackgroundResultInfluentialFeuerstein, J. D., & Cheifetz, A. S. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.07.002 · Cited by 378
Shen, J., Zuo, Z.-X., & Mao, A.-P. (2014) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000437495.30052.be · Cited by 364
“38 , 4 pouchitis, 20, 22 , 25, 39 for”
BackgroundInfluentialInteractions between Intestinal Microbiota and Host Immune Response in Inflammatory Bowel Disease
Zhang, M., Sun, K., Wu, Y., Yang, Y., Tso, P., & Wu, Z. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00942 · Cited by 347
AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis
Ko, C. W., Singh, S., Feuerstein, J. D., Falck-Ytter, C., Falck-Ytter, Y. T., Cross, R. K., Crockett, S. D., Falck-Ytter, Y. T., Feuerstein, J. D., Flamm, S. L., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.12.009 · Cited by 340
The human gut microbiome: current knowledge, challenges, and future directions
Dave, M., Higgins, P., Middha, S., & Rioux, K. P. (2012) · Translational research · doi:10.1016/j.trsl.2012.05.003 · Cited by 357
Kunde, S., Pham, A., Bonczyk, S., Crumb, T., Duba, M., Conrad, H., Cloney, D., & Kugathasan, S. (2013) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318292fa0d · Cited by 314
“Probiotics, for example, VSL#3, have shown some usefulness in the treatment of UC (5); however, not all probiotic formulations contain the same species, their efficacy may be strain specific, and understanding of their mechanism of action in the complex gastrointestinal (GI) microbiome is lacking.”
BackgroundGanji‐Arjenaki, M., & Rafieian‐Kopaei, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.25911 · Cited by 314
ESPEN practical guideline: Clinical Nutrition in inflammatory bowel disease
Bischoff, S. C., Escher, J., Hébuterne, X., Kłęk, S., Krznaric, Z., Schneider, S., Shamir, R., Stardelova, K., Wierdsma, N., Wiskin, A. E., et al. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2019.11.002 · Cited by 351
“A GRADE analysis indicated that the quality of evidence supporting this outcomewas low due to very sparse data (35 events) [171].”
BackgroundJakubczyk, D., Leszczyńska, K., & Górska, S. (2020) · Nutrients · doi:10.3390/nu12071973 · Cited by 323
“In another study, Tursi and co-workers checked the VLS#3 as an adjunct to the routinely used pharmaceutical treatment [98].”
BackgroundDupont, A. W., Richards, Jelinek, K. A., Krill, J. T., Rahimi, E. F., & Ghouri, Y. A. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s27530 · Cited by 303
Current and emerging drugs for the treatment of inflammatory bowel disease
Triantafillidis, J. K. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s11290 · Cited by 289
“81 Rembacken et al investigated whether the administration of a non-pathogenic strain of EcN was as effective as mesalazine in preventing relapse of UC as well as whether the addition of E. coli to standard medical therapy increased the rate of remission of active UC.”
Roles of Short-Chain Fatty Acids in Inflammatory Bowel Disease
Shin, Y., Han, S., Kwon, J., Ju, S., Choi, T., Kang, I., & Kim, S. S. (2023) · Nutrients · doi:10.3390/nu15204466 · Cited by 313
New Approaches for Bacteriotherapy: Prebiotics, New-Generation Probiotics, and Synbiotics
Patel, R., & DuPont, H. L. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ177 · Cited by 282
Bifidobacterium Longum: Protection against Inflammatory Bowel Disease
Yao, S., Zhao, Z., Wang, W., & Liu, X. (2021) · Journal of Immunology Research · doi:10.1155/2021/8030297 · Cited by 270
“VSL #3 131 (33-62 years old) 8weeks 3:6 × 109 CFU/day Clinical scores in UC ↓ [109]”
Rossi, G., Pengo, G., Caldín, M., Piccionello, A. P., Steiner, J. M., Cohen, N. D., Jergens, A. E., & Suchodolski, J. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094699 · Cited by 254
“The VSL#3 strains have shown efficacy in humans for the prevention, treatment, and maintenance of remission of both pouchitis and ulcerative colitis in adults and children [12,14,15].”
BackgroundMicrobiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities
Iliev, I. D., Ananthakrishnan, A. N., & Guo, C.-J. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01163-0 · Cited by 249
“An eight-strain mixture containing Lactobacillus spp., Bifidobacterium spp. and Streptococcus spp. (VSL#3, Actial) was more effective in inducing remission in mild-to-moderate UC than placebo 179 , as well as efficacy in preventing recurrent pouchitis 180 .”
Đorđević, Đ., Jančíková, S., Vítězová, M., & Kushkevych, I. V. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.03.003 · Cited by 249
Jonkers, D., Penders, J., Masclee, A., & Pierik, M. (2012) · Drugs · doi:10.2165/11632710-000000000-00000 · Cited by 240
“Two other large, well designed, randomized, placebo-controlled trials found significantly more patients with mild to moderately active UC to reach at least 50% improvement in clinical activity indices after VSL#3 compared with placebo treatment for 12 (n= 147)([79]) and 8 weeks (n = 144)([81]) based on ITT analyses.”
BackgroundMethodInfluentialvon Schillde, M., Hörmannsperger, G., Weiher, M., Alpert, C.-A., Hahne, H., Bäuerl, C., Huynegem, K. V., Steidler, L., Hrnčíř, T., Pérez‐Martínez, G., et al. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.02.006 · Cited by 244
Fedorak, R. N., Feagan, B. G., Hotte, N., Leddin, D., Dieleman, L. A., Petrunia, D. M., Enns, R. A., Bitton, A., Chiba, N., Paré, P., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.10.031 · Cited by 230
Vindigni, S. M., Zisman, T. L., Suskind, D. L., & Damman, C. J. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16644242 · Cited by 241
Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India
Kumari, R. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i22.3404 · Cited by 228
“Disease activity in UC patients was determined by simple clinical colitis activity index [18] and the patients with total index score of 7-10, > 10 and 0-2 were assigned moder - ate, severe and remission category, respectively [19] .”
Probiotics in Inflammatory Bowel Disease
Abraham, B. P., & Quigley, E. M. M. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2017.08.003 · Cited by 217
Bile Acid–Gut Microbiota Axis in Inflammatory Bowel Disease: From Bench to Bedside
Yang, M., Gu, Y., Li, L., Liu, T., Song, X., Sun, Y., Cao, X., Wang, B., Jiang, K., & Cao, H. (2021) · Nutrients · doi:10.3390/nu13093143 · Cited by 223
ACG Clinical Guideline Update: Ulcerative Colitis in Adults
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Barnes, E. L., & Long, M. D. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003463 · Cited by 226
“In one clinical trial using this probiotic as add-on therapy to 5-ASA, endoscopic improvement was not achieved (150).”
Gut Microbiota, Immunity, and Disease: A Complex Relationship
Kosiewicz, M. M., Zirnheld, A. L., & Alard, P. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00180 · Cited by 207
“…species (Bifidobacterium longum, Bifidobacterium breve, and Bifidobacterium infantis) and a Streptococcus salivarius subsp., Thermophilus, has been shown to decrease ulcerative colitis in patients with mild to moderately active ulcerative colitis (Sood et al., 2009; Tursi et al., 2010).”
BackgroundDevelopment of the Pediatric Gut Microbiome: Impact on Health and Disease
Ihekweazu, F. D., & Versalovic, J. A. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.08.005 · Cited by 205
Yılmaz, İ., Dolar, M. E., & Özpınar, H. (2019) · Turkish Journal of Gastroenterology · doi:10.5152/tjg.2018.18227 · Cited by 193
Zhang, X.-F., Guan, X.-X., Tang, Y.-J., Sun, J.-F., Wang, X.-K., Wang, W.-D., & Fan, J.-M. (2021) · European Journal of Nutrition · doi:10.1007/s00394-021-02503-5 · Cited by 193
Probiotics for maintenance of remission in ulcerative colitis
Iheozor‐Ejiofor, Z., Kaur, L., Gordon, M. A., Baines, P. A., Sinopoulou, V., & Akobeng, A. K. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007443.pub3 · Cited by 193
The intestinal microbiota in inflammatory bowel disease
Becker, C., Neurath, M. F., & Wirtz, S. (2015) · ILAR Journal · doi:10.1093/ilar/ilv030 · Cited by 185
“In several studies using VSL#3, treatment of patients with mild to moderate UC resulted in a combined induction of remission/response rate with no severe adverse effects (Sood et al. 2009; Tursi et al. 2010).”
Miele, E., Shamir, R., Aloi, M., Assa, A., Braegger, C., Bronsky, J., de Ridder, L., Escher, J. C., Hojsak, I., Kolaček, S., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001896 · Cited by 191
Probiotic Modulation of Innate Cell Pathogen Sensing and Signaling Events
Llewellyn, A., & Foey, A. (2017) · Nutrients · doi:10.3390/nu9101156 · Cited by 171
“Probiotics have been used to treat a range of health conditions encompassing intestinal and extraintestinal sites, including atopic dermatitis, necrotising enterocolitis, pouchitis and ulcerative colitis [142–144].”
Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease
Whelan, K., & Quigley, E. M. M. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835d7bba · Cited by 190
“boulardii, as well as Lactobacillus reuterii (by enema)([40]) and VSL#3([41]) in maintaining remission in ulcerative colitis and in treating mild to moderately active disease.”
BackgroundAhl, D., Liu, H., Schreiber, O., Roos, S., Phillipson, M., & Holm, L. (2016) · Acta Physiologica · doi:10.1111/apha.12695 · Cited by 182
The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy
Cammarota, G., Ianiro, G., Cianci, R., Bibbò, S., Gasbarrini, A., & Currò, D. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.006 · Cited by 184
“#3 probiotic mixture, administered for 6-12 weeks, in inducing the remission in patients with mildly-to-moderately active UC treated with conventional therapy (Bibiloni et al., 2005; Tursi et al., 2004; Tursi et al., 2010) or not receiving any other therapy (Lee et al., 2012; Sood et al., 2009).”
BackgroundSelf-citationIntestinal microbiota, probiotics and prebiotics in inflammatory bowel disease
Orel, R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i33.11505 · Cited by 177
Yan, F., & Polk, D. B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01428 · Cited by 181
Ulcerative colitis: molecular insights and intervention therapy
Liang, Y., Li, Y., Lee, C., Yu, Z., Chen, C., & Liang, C. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00207-w · Cited by 192
Intestinal Epithelial Barrier Dysfunction in Disease and Possible Therapeutical Interventions
Catalioto, R.-M., Maggi, C. A., & Giuliani, S. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794839179 · Cited by 172
Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets
Yadav, V., Varum, F., Bravo, R., Furrer, E., Bojic, D., & Basit, A. W. (2016) · Translational research · doi:10.1016/j.trsl.2016.04.009 · Cited by 174
Ponziani, F. R., Zocco, M. A., D’Aversa, F., Pompili, M., & Gasbarrini, A. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i25.4491 · Cited by 177
Self-citationIniesta, M., Herrera, D., Montero, E., Zurbriggen, M. M., Matos, A. R. F., Marín, M. J., Sánchez‐Beltrán, M. C., Llama‐Palacios, A., & Sanz, M. (2012) · Journal Of Clinical Periodontology · doi:10.1111/j.1600-051x.2012.01914.x · Cited by 167
Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders
Currò, D., Ianiro, G., Pecere, S., Bibbò, S., & Cammarota, G. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13632 · Cited by 160
“In several RCTs, it was effective in the induction of remission in patients with mild-to-moderate UC, together with conventional treatment (Tursi et al., 2004, 2010), or alone (Sood et al., 2009).”
MethodComplementary and Alternative Medicines Used by Patients With Inflammatory Bowel Diseases
Cheifetz, A. S., Gianotti, R. J., Luber, R. P., & Gibson, P. R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.10.004 · Cited by 166
Microbiome therapeutics: exploring the present scenario and challenges
Yadav, M., & Chauhan, N. S. (2021) · Gastroenterology report · doi:10.1093/gastro/goab046 · Cited by 164
A Gastroenterologist's Guide to Probiotics
Ciorba, M. A. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.03.024 · Cited by 156
Probiotics for induction of remission in ulcerative colitis
Kaur, L., Gordon, M. A., Baines, P. A., Iheozor‐Ejiofor, Z., Sinopoulou, V., & Akobeng, A. K. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005573.pub3 · Cited by 148
“• Minor adverse events were reported in nine studies (Kato 2004; Liu 2014; Matthes 2010; Miele 2009; Sood 2009; Tamaki 2016; Tursi 2010; Vejdani 2017; Zhang 2018a).”
BackgroundMethodInfluentialDiet therapy for inflammatory bowel diseases: The established and the new
Durchschein, F., Petritsch, W., & Hammer, H. F. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i7.2179 · Cited by 147
Probiotic mixture VSL# 3: An overview of basic and clinical studies in chronic diseases
Cheng, F.-S., Pan, D., Chang, B., Jiang, M., & Sang, L.-X. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i8.1361 · Cited by 147
Large-scale association analyses identify host factors influencing human gut microbiome compositionPreprint
Kurilshikov, A., Medina‐Gómez, C., Bacigalupe, R., Radjabzadeh, D., Wang, J., Demirkan, A., Roy, C. I. L., Garay, J. A. R., Finnicum, C. T., Liu, X., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.26.173724 · Cited by 143
Wang, Y., Xie, Q., Zhang, Y., Ma, W., Ning, K., Xiang, J., Cui, J., & Xiang, H. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10259-6 · Cited by 144
“Clinical studies have shown that probiotics can alleviate the symptoms of UC (Tursi et al. 2010) and maintain clinical remission (Yoshimatsu et al.”
BackgroundProbiotic Mix VSL#3 Is Effective Adjunctive Therapy for Mild to Moderately Active Ulcerative Colitis
Mardini, H. E., & Grigorian, A. Y. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000084 · Cited by 140
VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice
Wang, C.-S.-E., Li, W., Wang, H., Ma, Y., Zhao, X., Yang, H., Qian, J., & Li, J. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i37.4254 · Cited by 139
Dickerson, F., Adamos, M. B., Katsafanas, E., Khushalani, S., Origoni, A. E., Savage, C. L. G., Schweinfurth, L. A. B., Stallings, C. R., Sweeney, K., Goga, J. K., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12652 · Cited by 138
Torres, J., Ellul, P., Langhorst, J., Mikocka‐Walus, A. A., Acosta, M. B., Basnayake, C., Ding, N. S., Gilardi, D., Katsanos, K. H., Moser, G., et al. (2019) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjz051 · Cited by 143
Appleyard, C. B., Cruz, M. L., Isidro, A., Arthur, J. C., Jobin, C., & Simone, C. D. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00167.2011 · Cited by 130
Role of nutrition and microbiota in susceptibility to inflammatory bowel diseases
Gentschew, L., & Ferguson, L. R. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100630 · Cited by 133
The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study
Palumbo, V. D., Romeo, M., Marino, A., Carini, F., Damiani, P., Damiano, G., Buscemi, S., Monte, A. I. L., Geagea, A. G., Jurjus, A. R., et al. (2016) · Biomedical Papers · doi:10.5507/bp.2016.044 · Cited by 130
AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis
Singh, S., Feuerstein, J. D., Binion, D. G., & Tremaine, W. J. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.12.008 · Cited by 130
Cionci, N. B., Baffoni, L., Gaggìa, F., & Gioia, D. D. (2018) · Nutrients · doi:10.3390/nu10111723 · Cited by 138
“#3 administration in patients with diarrhoea predominant-IBS or functional diarrhoea; the probiotic intake caused changes in gut microbiota composition with a significantly increase of total lactobacilli, total bifidobacteria and S. thermophilus, which are component of VSL#3.”
ResultInfluentialAGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders
Preidis, G. A., Weizman, A. V., Kashyap, P., & Morgan, R. L. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.060 · Cited by 137
Emerging pharmacotherapy for inflammatory bowel diseases
Luo, H., Cao, G., Luo, C., Tan, D., Vong, C. T., Xu, Y., Wang, S., Lu, H., Wang, Y., & Jing, W. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106146 · Cited by 136
Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases
Dolan, K. T., & Chang, E. B. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600129 · Cited by 136
Probiotics, Prebiotics and Synbiotics in Inflammatory Bowel Diseases
Akutko, K., & Stawarski, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112466 · Cited by 133
“2010 [41] 144 adults higher efficacy of probiotic mixture as add-on therapy to conventional treatment in patients with relapsing disease compared to placebo”
BackgroundProbiotics and prebiotics in ulcerative colitis
Derikx, L. A. A. P., Dieleman, L. A., & Hoentjen, F. (2016) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2016.02.005 · Cited by 125
“The relatively low costs and excellent safety profile of probiotics and prebiotics make these therapies attractive for implementation into current treatment regimens [18,28,37].”
BackgroundInfluentialBasso, P. J., Câmara, N. O. S., & Sales‐Campos, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01571 · Cited by 121
Impact of air pollution on intestinal redox lipidome and microbiome
Feng, J., Cavallero, S., Hsiai, T. K., & Li, R. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.12.044 · Cited by 120
Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate
Gallo, A., Passaro, G., Gasbarrini, A., Landolfi, R., & Montalto, M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7186 · Cited by 122
Self-citationFecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis
Shi, Y., Dong, Y., Huang, W., Zhu, D., Mao, H., & Su, P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157259 · Cited by 121
Relationship between gut microbiota and development of T cell associated disease
Kosiewicz, M. M., Dryden, G. W., Chhabra, A., & Alard, P. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.019 · Cited by 120
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer
Gao, Z., Guo, B., Gao, R., Zhu, Q., Wu, W., & Qin, H. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4124 · Cited by 116
“Studies in animal models and humans have demonstrated that the consumption of probiotics is effective in various medical conditions, can delay senility (22), and improve acute infectious diarrhea (23,24), antibiotic‐associated diarrhea (21,25), constipation (26‐28), ulcerative colitis (29,30) and Crohn's disease (31,3…”
BackgroundProbiotics ameliorate intestinal pathophysiology in a mouse model of Alzheimer’s disease
Kaur, H., Nagamoto‐Combs, K., Golovko, S. A., Golovko, M. Y., Klug, M. G., & Combs, C. K. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.04.009 · Cited by 115
Prebiotics and Probiotics for Gastrointestinal Disorders
Rau, S., Gregg, A., Yaceczko, S. D., & Limketkai, B. N. (2024) · Nutrients · doi:10.3390/nu16060778 · Cited by 127
“® at 3600 × 10 9 CFU/day to improve disease activity scores and rectal bleeding, although the differences were not significantly different from placebo [145].”
BackgroundProbiotics for the Treatment of Inflammatory Bowel Disease
Veerappan, G. R., Betteridge, J. D., & Young, P. E. (2012) · Current Gastroenterology Reports · doi:10.1007/s11894-012-0265-5 · Cited by 117
D’Urso, F., & Broccolo, F. (2024) · Applied Sciences · doi:10.3390/app14198627 · Cited by 112
Astó, E., Méndez, I., Audivert, S., Farrán-Codina, A., & Espadaler, J. (2019) · Nutrients · doi:10.3390/nu11020293 · Cited by 117
Mills, S., Yang, B. K., Smith, G., Stanton, C., & Ross, R. P. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2186098 · Cited by 117
Metadata
- Authors
- Tursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G. M., Forti, G., Morini, S., Hassan, C., Pistoia, M. A., Modeo, M. E., Rodino', S., D'Amico, T., Sebkova, L., Sacca', N., Di Giulio, E., Luzza, F., Imeneo, M., Larussa, T., Di Rosa, S., Annese, V., Danese, S., & Gasbarrini, A.
- Affiliations
- Ospedale L. Bonomo (IT)
- Ospedale Cristo Re (IT)
- Agostino Gemelli University Polyclinic (IT)
- Azienda Ospedaliera Pugliese Ciaccio (IT)
- St. Eugenio Hospital (IT)
- Ospedale Santa Maria Goretti (IT)
- Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT)
- Azienda Ospedaliero-Universitaria "Renato Dulbecco" (IT)
- Casa Sollievo della Sofferenza (IT)
- Corresponding author
- Tursi, Antonio
- ORCID
- Venue
- American Journal of Gastroenterology
- Published
- 2010-10
- Volume
- 105
- Issue
- 10
- Pages
- 2218-2227
- ISSN
- 0002-9270 (ISSN-L)
- PMC
- PMC3180711
- OpenAlex
- W1998335236
- Cited by
- 489
- References
- 39
- Citations by year
- 2026: 10 · 2025: 22 · 2024: 35 · 2023: 30 · 2022: 29 · 2021: 28 · 2020: 46 · 2019: 31 · 2018: 39 · 2017: 38 · 2016: 28 · 2015: 29 · 2014: 38 · 2013: 27 · 2012: 28
- FWCI
- 15.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (unspecified)
- Locations
- The American Journal of Gastroenterology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi dell Aquila (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- ulcerative colitis, VSL#3, probiotics, adjunctive therapy, relapsing disease, 5-aminosalicylic acid, immunosuppressants, disease activity, rectal bleeding, stool frequency, inflammatory bowel disease treatment, pouchitis, Crohn's disease, irritable bowel syndrome, irritable bowel syndrome with diarrhea
- MeSH terms
- Adult, Azathioprine, Bifidobacterium, Colitis, Ulcerative, Combined Modality Therapy, Double-Blind Method, Female, Humans, Lactobacillus, Male, Middle Aged, Recurrence, Remission Induction, Severity of Illness Index, Treatment Outcome, Patient Selection, Mesalamine, Probiotics, Streptococcus thermophilus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
